NZ509645A - Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance P - Google Patents
Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance PInfo
- Publication number
- NZ509645A NZ509645A NZ509645A NZ50964599A NZ509645A NZ 509645 A NZ509645 A NZ 509645A NZ 509645 A NZ509645 A NZ 509645A NZ 50964599 A NZ50964599 A NZ 50964599A NZ 509645 A NZ509645 A NZ 509645A
- Authority
- NZ
- New Zealand
- Prior art keywords
- phenyl
- thienyl
- excess
- substance
- group
- Prior art date
Links
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 title abstract 3
- 230000001404 mediated effect Effects 0.000 title abstract 2
- 125000001544 thienyl group Chemical group 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 3
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 title 1
- 102100024304 Protachykinin-1 Human genes 0.000 title 1
- 101800003906 Substance P Proteins 0.000 title 1
- YKEKWOJUUNYRIR-UHFFFAOYSA-N methanol;1h-pyrazole Chemical class OC.C=1C=NNC=1 YKEKWOJUUNYRIR-UHFFFAOYSA-N 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 241000282414 Homo sapiens Species 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- -1 N-methylpiperidyl group Chemical group 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 201000001880 Sexual dysfunction Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 210000003169 central nervous system Anatomy 0.000 abstract 1
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000033001 locomotion Effects 0.000 abstract 1
- CWWARWOPSKGELM-SARDKLJWSA-N methyl (2s)-2-[[(2s)-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-5-amino-2-[[(2s)-5-amino-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-1-[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-5 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)OC)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 CWWARWOPSKGELM-SARDKLJWSA-N 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 231100000872 sexual dysfunction Toxicity 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| ES009801708A ES2150378B1 (es) | 1998-08-07 | 1998-08-07 | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p. |
| PCT/ES1999/000255 WO2000007542A2 (es) | 1998-08-07 | 1999-08-05 | Empleo de derivados de aril(o heteroaril)azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de los trastornos mediados por un exceso de substancia p |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ509645A true NZ509645A (en) | 2003-01-31 |
Family
ID=8304839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ509645A NZ509645A (en) | 1998-08-07 | 1999-08-05 | Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance P |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6518295B1 (enExample) |
| EP (1) | EP1103243B1 (enExample) |
| JP (1) | JP2002522359A (enExample) |
| KR (1) | KR100558506B1 (enExample) |
| CN (1) | CN1151789C (enExample) |
| AR (1) | AR019999A1 (enExample) |
| AT (1) | ATE257379T1 (enExample) |
| AU (1) | AU754124B2 (enExample) |
| BR (1) | BR9912807A (enExample) |
| CA (1) | CA2339661C (enExample) |
| CO (1) | CO5080747A1 (enExample) |
| CZ (1) | CZ292065B6 (enExample) |
| DE (1) | DE69914085T8 (enExample) |
| DK (1) | DK1103243T3 (enExample) |
| ES (2) | ES2150378B1 (enExample) |
| HU (1) | HUP0105428A3 (enExample) |
| IL (1) | IL141295A0 (enExample) |
| NO (1) | NO20010634L (enExample) |
| NZ (1) | NZ509645A (enExample) |
| PL (1) | PL193802B1 (enExample) |
| PT (1) | PT1103243E (enExample) |
| RU (1) | RU2223116C2 (enExample) |
| TR (1) | TR200100378T2 (enExample) |
| TW (1) | TW445259B (enExample) |
| WO (1) | WO2000007542A2 (enExample) |
| ZA (1) | ZA200100867B (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2174756B2 (es) * | 2001-04-06 | 2003-11-16 | Esteve Labor Dr | Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de enfermedades respiratorias. |
| ES2180449B1 (es) * | 2001-07-06 | 2004-01-16 | Esteve Labor Dr | Derivados de aril (o heteroaril) azolilcarbinoles para el tratamiento de la incontinencia urinaria. |
| US20040142929A1 (en) * | 2001-07-06 | 2004-07-22 | Ramon Merce-Vidal | Derivatives of aryl (or heteroaryl) azolylcarbinoles for the treatment of urinary incontinence |
| DE10335566A1 (de) * | 2003-07-31 | 2005-02-24 | Grünenthal GmbH | Arzneimittel enthaltend Derivate von Aryl( oder Heteroaryl)azolylcarbinolen |
| ES2244326B1 (es) * | 2004-04-05 | 2007-02-16 | Laboratorios Del Dr. Esteve, S.A. | Combinacion de substancias activas. |
| EP1584335A3 (en) * | 2004-04-05 | 2006-02-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising a carbinol composition and an opioid |
| EP1784178A1 (en) * | 2004-07-30 | 2007-05-16 | Laboratorios Del Dr. Esteve, S.A. | Aryl (or heteroaryl) azolylcarbinols |
| US20080045610A1 (en) * | 2004-09-23 | 2008-02-21 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| CA2580694A1 (en) * | 2004-09-23 | 2006-03-30 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
| ES2286920B1 (es) * | 2005-02-15 | 2008-08-16 | Laboratorios Del Dr. Esteve, S.A. | Derivados de aril (o heteroaril)azolilcarbinoles para el tratamiento de la fibromialgia. |
| EP1695704A1 (en) * | 2005-02-28 | 2006-08-30 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia |
| EP1690537A1 (en) * | 2005-02-15 | 2006-08-16 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl(or heteroaryl) azolycarbinols for the treatment of fibromyalgia |
| WO2006087147A2 (en) * | 2005-02-15 | 2006-08-24 | Laboratorios Del Dr. Esteve, S.A. | Derivatives of aryl (or heteroaryl) azolylcarbinols for the treatment of fibromyalgia |
| JP2009524617A (ja) | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | 置換２−イミダゾール又はイミダゾリン誘導体の使用 |
| EP1820502A1 (en) * | 2006-02-10 | 2007-08-22 | Laboratorios Del Dr. Esteve, S.A. | Active substance combination comprising azolylcarbinol compounds |
| CN101528710B (zh) | 2006-10-19 | 2012-11-07 | 弗·哈夫曼-拉罗切有限公司 | 氨基甲基-4-咪唑类 |
| MX2009004617A (es) | 2006-11-02 | 2009-05-22 | Hoffmann La Roche | 2-imidazoles sustituidos como moduladores de los receptores asociados con trazas de amina. |
| EP2084152A2 (en) | 2006-11-16 | 2009-08-05 | F. Hoffmann-Roche AG | Substituted 4-imidazoles |
| CN101190330A (zh) | 2006-11-30 | 2008-06-04 | 深圳市鼎兴生物医药技术开发有限公司 | 胆碱酯酶在拮抗速激肽药物中的应用 |
| JP2010513238A (ja) | 2006-12-13 | 2010-04-30 | エフ．ホフマン−ラ ロシュ アーゲー | 微量アミン関連受容体（ｔａａｒ）に対するリガンドとしての新規２−イミダゾール |
| KR101174191B1 (ko) | 2007-02-02 | 2012-08-14 | 에프. 호프만-라 로슈 아게 | 중추 신경계 장애의 치료용 ｔａａｒ1 리간드로서 2-아미노옥사졸린 |
| EP2121641B1 (en) | 2007-02-15 | 2014-09-24 | F. Hoffmann-La Roche AG | 2-aminooxazolines as taar1 ligands |
| MX2009013742A (es) | 2007-07-02 | 2010-01-26 | Hoffmann La Roche | 2-imidazolinas. |
| KR101150628B1 (ko) | 2007-07-03 | 2012-05-31 | 에프. 호프만-라 로슈 아게 | 4-이미다졸린 및 항우울제로서 이의 용도 |
| WO2009016048A1 (en) | 2007-07-27 | 2009-02-05 | F. Hoffmann-La Roche Ag | 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands |
| JP5341084B2 (ja) | 2007-08-03 | 2013-11-13 | エフ．ホフマン−ラ ロシュ アーゲー | Ｔａａｒ１リガンドとしてのピリジンカルボキシアミド及びベンズアミド誘導体 |
| US8242153B2 (en) | 2008-07-24 | 2012-08-14 | Hoffmann-La Roche Inc. | 4,5-dihydro-oxazol-2YL derivatives |
| WO2010123999A2 (en) * | 2009-04-21 | 2010-10-28 | Auspex Pharmaceuticals, Inc. | 1-methylpyrazole modulators of substance p, calcitonin gene-related peptide, adrenergic receptor, and/or 5-ht receptor |
| US8354441B2 (en) | 2009-11-11 | 2013-01-15 | Hoffmann-La Roche Inc. | Oxazoline derivatives |
| US9452980B2 (en) | 2009-12-22 | 2016-09-27 | Hoffmann-La Roche Inc. | Substituted benzamides |
| BR112018015389B1 (pt) | 2016-03-17 | 2023-12-19 | F. Hoffmann-La Roche Ag | Derivado de 5-etil-4-metil-pirazol-3-carboxamida, seu processo de fabricação, preparação farmacêutica oral e uso |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2613720B1 (fr) * | 1987-04-10 | 1990-01-19 | Esteve Labor Dr | Derives d'aryl-heteroaryl carbinols avec activite analgesique |
| FR2681322B1 (fr) * | 1991-09-12 | 1993-12-17 | Laboratorios Dr Esteve Sa | Derives d'aryl-heteroaryl-{n-[2-(3,4-dimethoxyphenyl)-ethyl]-n-methyl-3-aminopropoxy}-methane leur preparation et leur application en tant que medicaments . |
| CA2154116A1 (en) * | 1994-07-22 | 1996-01-23 | Philip Arthur Hipskind | 1-aryl-2-acetamidopentanone derivatives for use as tachykinin receptor antagonists |
| FR2742147B1 (fr) * | 1995-12-06 | 1998-02-27 | Esteve Labor Dr | Procede de separation de carbinols |
| CA2273807A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating schizophrenic disorders |
| ATE285776T1 (de) * | 1996-12-02 | 2005-01-15 | Merck Sharp & Dohme | Verfahren und vorrichtung zur kompensation von durch chrominanzsignalverarbeitung verursachten luminanzstörungen |
| CA2273853A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating cognitive disorders |
| WO1998024439A1 (en) * | 1996-12-02 | 1998-06-11 | Merck Sharp & Dohme Limited | Use of nk-1 receptor antagonists for treating severe anxiety disorders |
| ES2150353B1 (es) * | 1998-04-15 | 2001-07-01 | Esteve Labor Dr | Tienilazolilalcoxietanaminas, su preparacion y su aplicacion como medicamentos. |
-
1998
- 1998-08-07 ES ES009801708A patent/ES2150378B1/es not_active Expired - Fee Related
-
1999
- 1999-08-04 AR ARP990103870A patent/AR019999A1/es unknown
- 1999-08-04 CO CO99049291A patent/CO5080747A1/es unknown
- 1999-08-05 NZ NZ509645A patent/NZ509645A/xx unknown
- 1999-08-05 CA CA002339661A patent/CA2339661C/en not_active Expired - Fee Related
- 1999-08-05 CZ CZ2001412A patent/CZ292065B6/cs not_active IP Right Cessation
- 1999-08-05 PL PL99346221A patent/PL193802B1/pl not_active IP Right Cessation
- 1999-08-05 DK DK99940199T patent/DK1103243T3/da active
- 1999-08-05 BR BR9912807-1A patent/BR9912807A/pt not_active Application Discontinuation
- 1999-08-05 AT AT99940199T patent/ATE257379T1/de not_active IP Right Cessation
- 1999-08-05 AU AU54229/99A patent/AU754124B2/en not_active Ceased
- 1999-08-05 JP JP2000563228A patent/JP2002522359A/ja active Pending
- 1999-08-05 DE DE69914085T patent/DE69914085T8/de not_active Expired - Fee Related
- 1999-08-05 WO PCT/ES1999/000255 patent/WO2000007542A2/es not_active Ceased
- 1999-08-05 RU RU2001106644/15A patent/RU2223116C2/ru not_active IP Right Cessation
- 1999-08-05 EP EP99940199A patent/EP1103243B1/en not_active Expired - Lifetime
- 1999-08-05 ES ES99940199T patent/ES2213380T3/es not_active Expired - Lifetime
- 1999-08-05 PT PT99940199T patent/PT1103243E/pt unknown
- 1999-08-05 TR TR2001/00378T patent/TR200100378T2/xx unknown
- 1999-08-05 TW TW088113353A patent/TW445259B/zh not_active IP Right Cessation
- 1999-08-05 CN CNB998109150A patent/CN1151789C/zh not_active Expired - Fee Related
- 1999-08-05 HU HU0105428A patent/HUP0105428A3/hu unknown
- 1999-08-05 KR KR1020017001560A patent/KR100558506B1/ko not_active Expired - Fee Related
- 1999-08-05 US US09/762,079 patent/US6518295B1/en not_active Expired - Fee Related
-
2001
- 2001-01-31 ZA ZA200100867A patent/ZA200100867B/en unknown
- 2001-02-06 NO NO20010634A patent/NO20010634L/no not_active Application Discontinuation
- 2001-02-07 IL IL14129501A patent/IL141295A0/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ509645A (en) | Utilization of phenyl or thienyl subtituted imidazole or pyrazole carbinol derivatives for treating conditions mediated by an excess of substance P | |
| IL190780A0 (en) | Heterocyclic substituted aminoazacycles useful as central nervous system agents | |
| DE60037892D1 (de) | Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis | |
| MY133619A (en) | Tricyclic pyrazole derivatives | |
| DE60106641D1 (de) | Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten | |
| WO2003053922A3 (en) | Heteroaryl substituted imidazole modulators of metabotropic glutamate receptor-5 | |
| ATE453620T1 (de) | Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten | |
| BG104853A (en) | Thienylazolylalcoxyethanamines, their preparation and their application as medicaments | |
| WO2003039451A3 (en) | Thiazole pyridazinones as adenosine antagonists | |
| NZ514777A (en) | N6 heterocyclic 5'-thio substituted adenosine derivatives | |
| MXPA02011417A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas de receptores muscarinicos. | |
| EP1719761A4 (en) | NEW HETEROCYCLIC CONNECTION | |
| HUP9801340A1 (hu) | Triciklusos pirazolszármazékok és az azokat tartalmazó gyógyszerkészítmények | |
| AU6947401A (en) | Phenylpyridazine derivatives and drugs containing the same | |
| MXPA02011418A (es) | 1-aminoalquil-lactamas sustituidas y su uso como antagonistas del receptor muscarinico. | |
| HRP20010512B1 (en) | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds | |
| HU9301155D0 (en) | Methods for producing steroide derivatives and for their application in medical treatment | |
| ATE161535T1 (de) | 6,11-dihydro-5h-pyrido(2,3-b)(1,5)benzodiazepin 5-one und thione und ihre verwendung für die vorbeugung oder behandlung von aids | |
| WO2000071520A3 (en) | Aryl substituted alkylamines capable of activating nicotinic cholinergic receptors | |
| GR3025482T3 (en) | Heterocyclic amines having central nervous system activity | |
| DE69925160D1 (de) | Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität | |
| ES2137136B1 (es) | Empleo de derivados de aril (o heteroaril) azolilcarbinoles en la elaboracion de un medicamento para el tratamiento de la inflamacion neurogenica. | |
| AU2287499A (en) | Azetidinecarboxamide derivatives for treating cns disorders | |
| MY121785A (en) | Hydroxamic acid derivatives as inhibitors of the production of soluble cd23 | |
| NZ335493A (en) | Substituted 4-(6-fluoro-(1h)-indol-3-yl)-1,2,3,6-tetrahydropyridine for the treatment of CNS-disorders |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) | ||
| RENW | Renewal (renewal fees accepted) |